CORPORATE HISTORY

PlexBio Timeline

2009

2009. 12

 PlexBio Co., Ltd was established with a registered capital of $52,600,000 NT

2010. 06

Establishment of HongKong Co., Limited

2010. 10

Completed factory set-up registration

Establishment of HongKong Co., Limited

2010

2011

2011. 04

Signed a contract with the Instrument technology Research Center of the Nation Research Laboratory (NAR Lab) in July 2011 to develop digital analyzer phase I

2011. 10

Collaborated with Cathy general Hospital to complete a clinical trial on the screening of diagnostic reagent in 150 HPV cases, which paved the way for subsequent development of IntelliPlex series using digital analyzer phase I.

2011. 12

Establishment of Research Centers for Applied Proteomics

2012. 04

Introduced PlexBio 100 Analyzer and PlexBio Thermo Shaker

2012. 12

Introduced ISO/GMP quality systems and certified plant

2012

2013

2013. 03

Introduced PlexBio 100 Analyzer and PlexBio Thermo Shaker

2013. 04

Completed a round of Fund raising of NTD $97 million at $15 per share; Total of NTD $270 million paid-in capital was raised

2013. 07

Obtained ISO 9001, ISO 13485, GMP and CE Certifications for PlexBio Analyzer

2012. 08

Obtained TFDA's approval for PlexBio Analyzer

2013. 12

Establishment of Jiangsu PlexBio Medical Technology Co., Limited. Introduced PlexBio Thermocycler

2014. 02

Complete a round of fund-raising of NTD $272 million at $22 per share, total of NTD $380 million paid-in capital was raisied 

2014. 12

Obtained CFDA's import license for PlexBio Analyzer

Qualified for GMP Production of IHC reagents and Kits 

2014

2015

2015. 01

FISH Probe Kit passed ISO 9001 and ISO 13485

Obtained TFDA's approval for TERC and HERZ

2015. 02

Introduced PlexBo Wash Station

2015. 04

Obtained CE certificates for bDNA HPV ~ KRAS ' BRAF ~ EGFR and wash station

KRAS clinical trial began

2015. 11

Completed a round of fund'raising of NTD $350 million at $35 per share; total of NTD $508 million paid-in capital was raised

2016. 01

Supplemental public issuance took effect

Completed nCode MicroDisc development

2016. 02

Listed company at Taiwan emerging stock market

2016. 09

 License agreements signed with Denka Seiken Co.. Ltd.

2016

2017

2017. 02

Received TFDA certification for PlexBio™ 100 Fluorescent Analyzer 100 Fluorescent Analyzer

2017 03

Received TFDA certification for IntelliPlex™ 1000 πCode Processor

2017. 04

Received CE-IVD approval for IntelliPlex™ ALK Rearragnement Kit and HPV Genotyping Kits


PlexBio made its debut in presenting IntelliPlex CE-IVD reagents and test results to the scientific community at Molecular Diagnostics Europe conference

2017. 09

Received CE-IVD approval for IntelliPlex™ 1000 πCode Processor

2017. 11

Received CE-IVD approval for IntelliPlex™ ROS 1, RET/NTRK1 Rearrangement Kit, IntelliPlex™ KRAS Plus Mutation Kit, IntelliPlex™NRAS Mutation Kit

2017. 12

IntelliPlex™ HCV Genotyping Kit finished clinical trial, began data base lock


Passed ISO 13485:2003 SGS auditing- received certification renewal

2018. 01

PlexBio received Deloitte Technology Fast 500 Asia Pacific recognition - Ranks Among Top Growing Companies in Asia Pacific


PlexBio Expanded Collaboration with Denka to Co-Develop an Infectious Disease Diagnostic System

2018. 05

Euroclone Signed Distribution Agreements with PlexBio for the IntelliPlex™ Instrument System and Reagent

 

University "G. D'Annunzio" of Chieti Presented Data on PlexBio Technology at Molecular Diagnostic Europe Conference

2018. 08

Received TFDA Licenses for IntelliPlex™ KRAS and KRAS+ Mutation Kits

Denka Signed Distribution Agreements with PlexBio for the IntelliPlex™ Instrument System and Reagents

2018. 10

PlexBio Received CE-IVD Mark for IntelliPlex™ Lung Cancer Panel

2018